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ABSTRACT
The percutaneous absorption of 3H-betamethasone-17-valerate was studied in young
domestic pigs. Our findings suggest that this animal may serve as a suitable model for
studying the absorption of steroids from the skin. A single application of radioactive
cream was applied to the skin and kept there for three days under occlusion. Urine
proved to be the main excretory route of this topical steroid. Excretion in feces was
ten times less. After three days occlusion, an appreciable amount of radioactivity was
recovered from all tissues; highest concentrations were present in the liver. Plasma
samples revealed significant levels of radioactivity as early as two hours after applica-
tion and reached their highest concentrations at the end of 72 hours. After a single
application, maximal levels of radioactivity were also observed to persist in plasma for
a period of nine days in the presence of constant occlusion. These findings are discussed
with reference to the clinical use of topically applied steroids.
The beneficial therapeutic effects of steroids
have been well demonstrated. However relatively
little is known about plasma and tissue levels
of these compounds when they are applied
to the skin.
The study of the distribution of steroids ap-
plied topically may therefore be able to provide
additional information about their absorption
and undesirable systemic effects.
Clinically, side effects such as sodium re-
tention and weight gain have been reported by
Fitzpatrick et at. (1) and by Livingood et at.
(2) after the percutaneous absorption of fludro-
cortisone. Scoggins and Kliman (3) observed
pituitary-adrenal suppression and decreases in
endogenous cortisol levels following the topical
application of corticosteroids.
In addition, information about the distribu-
tion of steroids into various body compartments
has been obtained with the use of labeled com-
pounds which permit the measurement of radio-
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activity in body fluids. Thus Malkinson et at.
(4) showed that radioactivity was present in the
urine after hydroeortisone-4-14C was applied to
normal human skin. Similar observations have
been made for 14C-hydrocortisone by Feldmann
and Maibach (5), for ieCtriamcinolone aceto-
nide by Malkinson and Kirschenbaum (6) and
for 'H-betamethasone-17-valerate by Butler
(7).
However, reports on the plasma, fecal and
tissue distribution of topically administered
steroids are lacking, although Florini et at. (8)
studied plasma half-life and excretion of 8H-
triamcinolone in dogs and rats, and tissue dis-
tribution in the rat, after the intravenous ad-
ministration of this compound.
In this study, we report the concentration
and distribution of betamethasone-17-valerate
in plasma, urine, feces and tissues when this
tritium labeled steroid is applied to the skin of
the domestic pig.
MATERIALS AND METHODS
Domestic piglets of either sex varying in weight
from 20 to 48 pounds were used in this study.
Radioactive steroid cream was made with tritium
labeled betamethasone-17-valerate, with a specific
activity of 3.3 me/mg (New England Nuclear
Corporation of Boston, Mass.). This product was
purified further using thin layer chromatography
in a solvent system of ethyl acetate/cyclohexane,
2:1. Approximately 60 micrograms of purified
tritiated betamethasone-17-valerate of known dis-
integrations per minute (DPM) was incorporated
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into 9.0 gm of a cream base identical in composi-
tion to that used by Schering Corporation in the
preparation of Celestoderm Cream®.
Under Halothane® anesthesia, the skin of the
back of each pig was shaved and irritated with
sandpaper. The radioactive betamethasone cream
was then applied to a six by six inch area which
was covered immediately with Saran Wrap® (Dow
Chemical Corp.) and a protective dressing. Eight
pigs treated in this manner were kept in metabolic
cages for the duration of this study. Saran Wrap®
dressings were left on the backs of the first seven
pigs for 72 hours and on an additional eighth pig
for 9 days.
Blood samples of 1 ml were obtained from the
ear veins and collected in heparinized tubes at 2,
4, 24, 30, 48, 54 and 72 hours. The plasma was
removed, frozen immediately and stored at l00
C. Twenty-four hour urine and feces samples were
also frozen and stored for future analyses.
At the end of each 72 hour treatment period,
pigs were anesthetized and exsanguinated to mini-
mize radioactive contamination of tissues and
organs removed during autopsy. With the excep-
tion of the gastro-intestinal tract, all organs were
weighed and samples of approximately 50 mg were
taken for evaluation of their radioactive content.
Small pieces of the Saran Wrap® and skin at the
site of application were also removed for analysis.
0.4 ml of NCS solubilizer®, (a quaternary ammo-
nium base in a 0.6 N Toluene solution) obtained
from Nuclear Chicago Corporation was added to
the samples of Saran Wrap® and skin, and 0.2 ml
was added to all organ and tissue samples to digest
them. The steroid, betamethasone-17-valerate was
extracted from feces with methanol.
Modified Bray's solution1 (10 ml) was added to
all plasma, urine, feces and digested organ
samples, and radioactive determinations were made
with a Mark 1 Nuclear Chicago Liquid Scintilla-
tion Counter. The channels ratio method was used
to correct all samples for variations in counting
efficiencies; the results were expressed as dis-
integrations per minute (DPM).
Since in a number of cases, the percentage of
the absorbed dose showed wide variations and yet
only positive values were meaningful, these meas-
urements were considered as being log normally
distributed. The arithmetic means and standard
errors were calculated for the logarithms of these
measurements, and these statistics reconverted to
the original percentage scale giving geometric
means with their equivalent standard errors.
RESULTS
Figure 1 illustrates the mean levels of radio-
activity (five pigs) recovered in plasma at 2, 4,
24, 30, 48, 54 and 72 hour intervals. The graph
is expressed as a percentage of the absorbed
PPM and shows significant values at 2 hours
1 1 gallon Dioxane, 400 gm Naphthalene, 28 gm
PPO, 12 gm POPOP.
with a linear increase thereafter to attain the
highest value at 72 hours (0.68 0.13%).
Table I indicates that at the end of 72 hours,
11.0 2.3% of the total DPM absorbed had
been recovered in the urine; 1.4 0.4% was
present in the feces and the content of the or-
gans studied accounted for 6.8 2.7%. When
expressed as a percentage of the total DPM
applied, the plasma, urine, feces and organs
radioactivity amounted to 19.9 3.6%. The
Saran Wrap® and the six by six inch piece of
skin at the site of application yielded 12.2
3.5% of the total DPM applied. Thus, a total
of 32.1 5.0% of the initial radioactivity was
recovered. In this study, no attempts were made
to determine the amount of radioactivity in the
muscle mass, skeleton and other areas of the
skin; it is therefore possible that the remaining
67.9% of the total dose applied may be partially
localized in these structures, and in part either
secreted by sweat glands or lost during expira-
tion.
The evaluation of the tissue distribution of
labeled betamethasone-17-valerate presented
certain difficulties. Severe quenching occurred
from the use of a potent quaternary ammonium
base tissue-dissolving reagent and as a result of
the yellow color of the chemically treated
tissues. In the first pig, there was an apparent
high concentration of activity in the pituitary
and adrenals when compared to other tissues.
Subsequent animals did not show this preferen-
tial concentration. The greatest activity was
concentrated in the liver and the total meait
recovery in the organs studied was 6.8 2.7%.
In order to evaluate the reproducibility of our
experimental technique, two pigs (numbers 6
and 7) of approximately the same size and
weight (14.3 and 12.2 kg) were topically treated
with radioactive cream containing respectively
380 X 106 PPM and 360 x 10 DPM, using
the experimental conditions outlined in materials
and methods. Figure 2 illustrates average levels
of radioactivity obtained from the urine and
feces of the two pigs used in this experiment.
These levels were similar in both pigs with a
maximal daily urinary excretion at 24 hours
and maximal fecal activity at 48 hours. In the
urine, pig 6 excreted 15.1 x 106 PPM during
the first 24 hours while pig 7 had a value of
13.6 x 10 DPM during the same period.
Plasma levels of radioactivity were also similar
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in both pigs and reached their maximal levels
at 72 hours; at the end of this period, pigs 6
and 7 showed values of 2.9 x 100 and 2.1 X
108 DPM respectively. It is of interest that the
urine output of radioactivity reached its peak
level before the plasma level had attained its
maximal value. One possible explanation for
this observation may be related to the fact that
plasma samples were collected and analysed at
specific time intervals, whereas urine values
represent voided urine which was collected for
24 hours and analysed at the end of that period.
An indwelling urinary catheter which would
permit collection of urinary samples at specific
time periods should provide a more accurate
reflection of a time course relationship between
plasma and urinary excretion values.
Since the level of radioactivity in the plasma
4 24O 44
Time in Hours
FIG. 1. Mean levels of radioactivity in plasma
TABLE I
Percutaneous absorption of 3H betamethasone-1 7-
valerate after lB hrs. application with occlusion
°
Total DPM
absorbed
% of total
DPM applied
Plasma 0.68 0.13t
Urine 11.0 2.3
Feces 1.4 0.4
Organs 6.8 2.7
SR+SK* 12.2±3.5P+U+F+O 19.9±3.6P+U+F+0+ 32.1±5.0
SR + SK
* SR = Saran wrap, SK = Skin, P = Plasma,U = Urine, F = Feces, 0 = Organs.
f Geometric Mean Equivalent Standard
Error.
showed maximal values at the end of the 72
hour period, it was of interest to determine
whether further increase in plasma radioactivity2 would be present over a longer period. To test
this possibility, the Saran Wrap® and protective
dressing were left on an additional pig for a
period of 9 days. Plasma and urine samples
were taken daily; these results are illustrated
in figure 3. The highest radioactivity in plasma
occurred on the second day and was 4.0 X 108
DPM. Minor fluctuations from this value were
observed for the following week, and 3.2 x 100
DPM was obtained on the 9th day. Urine, how-
ever, showed marked changes daily. The peak
daily excretion of 28 x 10° DPM occured on
the 2nd day and decreased to a final value on
the 9th day of 1.6 x 10° DPM. The total cumu-
lative (for nine days) urinary radioactivity
was 72 x 108 DPM (15% of total DPM ap-
plied).
DISCUSSION
The results indicate clearly that betametha-
sone-17-valerate is absorbed from the skin of
x 106 DPM
0
2
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C
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DAYS
FIG. 2. Levels of radioactivity. The solid line
represents the average of values obtained in two
pigs. Triangle: Pig 6. Circle: Pig 7.
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the domestic pig, and that significant levels
can be found in plasma two hours after applica-
tion. Since some similarities exist between por-
cine and human skin it is likely that a similar
rate of percutaneous absorption may also occur
in man; however, histological dissimilarities
have also been pointed out by Montagna (9)
and further comparative studies of the absorp-
tive characteristics of the skin of man and the
pig are needed.
Over a 72 hour period plasma levels of radio-
activity showed an initial rapid increase and
gradually reached maximal activity at 72 hours.
The initial entry of the labeled steroid into
circulation may be due, in part, to rapid ab-
sorption via the follicular pathway as described
by Feldinann and Maibach (5), and in part, to
the experimental condition of the animal's skin
which was slight1 irritated to produce hyper-
emia, often associated with inflammatory re-
actions of the sun. Comparison of the histo-
logical analysis of normal skin with that of the
skin treated lighl ly with sandpaper (5 strokes
in either directio:) did not reveal any appre-
ciable differences; mild erythema was observed
when the skin was irritated but no damage to
the stratum corneum was visible under micro-
scopic examination. This area was also occluded
with Saran Wrap® and clear evidence has
been presented by McKenzie and Stoughton
(10) that such a procedure will enhance the
absorption of topical steroids 100-fold.
Our observation that high plasma levels ob-
tained at 72 hours continued to persist until
the ninth day is also of interest. Vickers (11)
has described a stratum corneum reservoir for
topically applied steroids which is capable of
releasing the betamethasone-17-valerate when
permissive conditions such as occlusion are in
constant operation. It is also possible that the
consistently high plasma levels of radioactivity
may have resulted from tissue sources. Cope
(12) has described the uncertain fate of steroids
located in tissues. He suggests that they are
held there for a short time and are then re-
leased with or without chemical change. This
view has also been discussed by Tait et ol. (13).
Florini and his co-workers (8) noted that after
intravenous administration, the labeled steroid
was rapidly taken up by muscle and was equal
in concentration to that of blood. After twi
hours, the amount of steroid in blood was less
than that found in muscle, supporting the possi-
bility that the labeled steroid or its metabolic
products may be more firmly bound to muscle
than to blood proteins.
The percentage of betamethasone-17-valerate
excreted in the urine of the pig was 11.0
2.3%. This value is similar to that observed in
man. Studies by Butler (7) have shown that
urine is the main excretory route of betametha-
sone-17-valerate. In her studies, a patient with
pemphigus who had 20% of the body area
occluded for 3 days, excreted 18.5% of the
total applied dose. In our experiments, 1.4
0.4% of the total absorbed dose was recovered
in feces and this is in agreement with reports
in man (7) where similar percentages (1.6 to
3.5%) were found in feces after intravenous or
oral administration of 3H-betamethasone-17-
valerate.
When a single application of labeled steroid
cream was kept under occlusion for three days,
the plasma levels of activity progressively
increased and reached maximal values at 72
hours. In these pigs, 12.2 3.5% of the total
dose applied still remained on the Saran
Wrap® and at the skin site of application. The
results obtained when a single application of
H-betamethasone-17-valerate cream was left
in place, under occlusion, for nine days are also
of interest. Under these conditions, the plasma
radioactivity was maintained at consistently
high levels throughout the duration of the ex-
periment, and it is possible that the stratum
Time in Days
Fic. 3. Levels of radioactivity in plasma and
urine during nine days of occlusion.
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corneum reservoir described by Vickers (11)
may influence steroid plasma levels when per-
missive conditions such as occlusion are in con-
stant operation. This possibility has been
raised by Kirketerp (14) who suggested utiliz-
ing this reservoir therapeutically by changing
the occlusive plastic film dressing daily while
applying the steroid cream every third or
fourth day. Scoggins and Kliman (15) have
made the interesting observation that in some
concentrations the percutaneous steroid dose
necessary to bring about adrenal suppression is
quite close to the suppressing oral dose. This
suggested to them that a given dose could be
more potent when given percutaneously than
when given intermittently by the oral route.
The "alternate-day" regime of oral corticos-
teroid therapy which was proposed independ-
ently by Reichiing et al. (16) and by Harter
et al. (17) has succeeded in reducing the inci-
dence and severity of clinical side effects with-
out minimizing the desired therapeutic benefits.
The possibility exists that a similar treatment
schedule using topical steroids could yield re-
suits of clinical importance.
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